<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GELNIQUE- oxybutynin gel </strong><br>Actavis Pharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use GELNIQUE 3% safely and effectively. See full prescribing information for GELNIQUE 3%.</span><br><span class="Bold"><br>GELNIQUE 3% (oxybutynin) gel 3%, for topical use </span><span class="Bold"><br>Initial U.S. Approval: 1975</span><br>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Central Nervous System Effects (<a href="#_5_5_Central_Nervous">5.5</a>)   
		     
	07/2015 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">GELNIQUE 3% is a muscarinic receptor antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and frequency. (<a href="#_1_INDICATIONS_AND">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Apply three pumps of GELNIQUE 3% (84 mg) once daily to clean and dry, intact skin on the abdomen, or upper arms/shoulders, or thighs. (<a href="#_2_DOSAGE_AND">2</a>)<br>
</li>
<li>Application site may be rotated if necessary. (<a href="#_2_DOSAGE_AND">2</a>)<br>
</li>
<li>GELNIQUE 3% is for topical application only and should not be ingested. (<a href="#_2_DOSAGE_AND">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta"> Gel; 3% (<a href="#_3_DOSAGE_FORMS">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> (<a href="#_4_CONTRAINDICATIONS">4</a>)<br>
</li>
<li>Gastric retention (<a href="#_4_CONTRAINDICATIONS">4</a>)<br>
</li>
<li>Uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#_4_CONTRAINDICATIONS">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></span>: Caution should be exercised in patients with clinically significant bladder outflow obstruction because of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> risk. (<a href="#_5_1_Urinary_Retention">5.1</a>)<br>
</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: Use with caution in patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> and/or those taking drugs that can cause or exacerbate <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and in patients with decreased intestinal motility or gastrointestinal obstructive disorders because of the risk of gastric retention. (<a href="#_5_2_Use_in">5.2</a>)<br>
</li>
<li>
<span class="Underline">Skin Transference</span>: Advise patients to cover the application site with clothing if skin-to-skin contact at the application site is anticipated. Wash hands immediately after product application. (<a href="#_5_3_Skin_Transference">5.3</a>)<br>
</li>
<li>
<span class="Underline">Flammable Gel</span>: Contains alcohol-based gel. Avoid open fire or smoking until the gel has dried. (<a href="#_5_4_Flammable_Gel">5.4</a>)<br>
</li>
<li>
<span class="Underline">Central Nervous System Effects</span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> has been reported with drugs containing oxybutynin. Advise patients not to drive or operate heavy machinery until they know how GELNIQUE 3% affects them. (<a href="#_5_5_Central_Nervous">5.5</a>)<br>
</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></span>: Administer GELNIQUE 3% with caution in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, a disease characterized by decreased cholinergic activity at the neuromuscular junction. (<a href="#_5_6_Myasthenia_Gravis">5.6</a>)<br>
</li>
<li>
<span class="Underline"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> has been reported with oral oxybutynin use. If symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> occur, discontinue GELNIQUE 3% and initiate appropriate therapy. (<a href="#_5_7_Angioedema">5.7</a>)<br>
</li>
<li>
<span class="Underline">Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span>: Administer GELNIQUE 3% with caution in patients being treated for narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. (<a href="#_5_8_Controlled_Narrow_Angle">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 3%) are <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span>. (<a href="#_6_1_Clinical_Trials">6.1</a>) </p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Concomitant use with other anticholinergic (antimuscarinic) agents may increase the frequency and/or severity of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and other anticholinergic pharmacological effects. (<a href="#_7_1_Other_Anticholinergics">7.1</a>)</li></ul></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1 INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></a></h1>
<h1><a href="#section-3" class="toc"><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4 CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 Use in Patients with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 Skin Transference</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Flammable Gel</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 Central Nervous System Effects</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8 Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6 ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 Clinical Trials Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.</span><span class="Bold">2</span><span class="Bold"> </span><span class="Bold">Po</span><span class="Bold">s</span><span class="Bold">t</span><span class="Bold">m</span><span class="Bold">a</span><span class="Bold">r</span><span class="Bold">k</span><span class="Bold">e</span><span class="Bold">t</span><span class="Bold">ing</span><span class="Bold"> </span><span class="Bold">E</span><span class="Bold">x</span><span class="Bold">perie</span><span class="Bold">n</span><span class="Bold">ce</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7 DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 Other Anticholinergics</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2 Labor and Delivery</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3 Nursing Mothers</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4 Pediatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5 Geriatric Use</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-8.7" class="toc"><span class="Bold">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10 OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11 DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12 CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.3 Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14 CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_1_INDICATIONS_AND"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1 INDICATIONS AND USAGE</span></h1>
<p class="First">GELNIQUE 3% (oxybutynin) gel 3% is a muscarinic receptor antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and frequency <span class="Italics">[see </span><span class="Italics"><a href="#_14_CLINICAL_STUDIES">Clinical Studies (14)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_2_DOSAGE_AND"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">The recommended dosage is three pumps of GELNIQUE 3% (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs. Apply immediately after actuating the dose.  Application sites may be rotated to reduce the potential for local site reactions <span class="Italics">[see </span><span class="Italics"><a href="#_6_1_Clinical_Trials">Adverse Reactions (6.1)</a></span>]. GELNIQUE 3% is for topical application only and should not be ingested.</p>
<p>Wash hands immediately after product application. Patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated <span class="Italics">[see </span><span class="Italics"><a href="#_5_3_Skin_Transference">Warnings and Precautions (5.3)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3_DOSAGE_FORMS"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></h1>
<p class="First">GELNIQUE 3% is a homogeneous, colorless to slightly colored gel 3%.  </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_4_CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4 CONTRAINDICATIONS</span></h1>
<p class="First">The use of GELNIQUE 3% is contraindicated in patients with the following conditions:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> <span class="Italics">[see </span><span class="Italics"><a href="#_5_1_Urinary_Retention">Warnings and Precautions (5.1)</a></span>]<span class="Italics">.</span><br>
</li>
<li>Gastric retention <span class="Italics">[see </span><span class="Italics"><a href="#_5_2_Use_in">Warnings and Precautions (5.2)</a></span>].<br>
</li>
<li>Uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> <span class="Italics">[see </span><span class="Italics"><a href="#_5_8_Controlled_Narrow_Angle">Warnings and Precautions (5.8)</a></span><span class="Italics">].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_1_Urinary_Retention"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></span></h2>
<p class="First">Use GELNIQUE 3% with caution in patients with clinically significant bladder outflow obstruction because of the risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_2_Use_in"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 Use in Patients with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></h2>
<p class="First">Use GELNIQUE 3% with caution in patients with gastrointestinal obstructive disorders because of the risk of gastric retention.</p>
<p>GELNIQUE 3%, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or intestinal atony. </p>
<p>GELNIQUE 3% should be used with caution in patients who have <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_3_Skin_Transference"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 Skin Transference</span></h2>
<p class="First">Transfer of oxybutynin to another person can occur when vigorous bare skin-to-skin contact is made with the application site. To minimize the potential transfer of oxybutynin from treated skin to another person, patients should cover the application site with clothing after the gel has dried if direct skin-to-skin contact at the application site is anticipated <span class="Italics">[see </span><span class="Italics"><a href="#_12_3_Pharmacokinetics">Clinical Pharmacology (12.3)</a></span>]. Patients should wash their hands immediately after application of GELNIQUE 3%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_4_Flammable_Gel"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Flammable Gel</span></h2>
<p class="First">GELNIQUE 3% is an alcohol-based gel and is therefore flammable. Avoid open fire or smoking until gel has dried. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_5_Central_Nervous"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 Central Nervous System Effects</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Drugs containing oxybutynin are associated with anticholinergic central nervous system (CNS) effects<span class="Italics">.</span> A variety of CNS anticholinergic effects have been reported, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and hallucinations . Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment. Advise patients not to drive or operate heavy machinery until they know how GELNIQUE 3% affects them. If a patient experiences anticholinergic CNS effects, drug discontinuation should be considered.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_6_Myasthenia_Gravis"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></span></h2>
<p class="First">Administer GELNIQUE 3% with caution in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, a disease characterized by decreased cholinergic activity at the neuromuscular junction. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_7_Angioedema"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral oxybutynin.  In the event of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, oxybutynin containing product should be discontinued and appropriate therapy promptly provided. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_8_Controlled_Narrow_Angle"></a><a name="section-5.8"></a><p></p>
<h2><span class="Bold">5.8 Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></h2>
<p class="First">Administer GELNIQUE 3% with caution in patients being treated for narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1><span class="Bold">6 ADVERSE REACTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_6_1_Clinical_Trials"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">6.1 Clinical Trials Experience</span></h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of GELNIQUE 3% was evaluated in 626 patients (210 randomized to GELNIQUE 3% 56 mg/day, 214 randomized to GELNIQUE 3% 84 mg/day and 202 randomized to placebo) during a randomized, placebo-controlled, double-blind, 12-week clinical efficacy and safety study. A subset of these 626 patients (N = 77) participated in the 24-week open-label safety extension that followed the placebo-controlled study. Of the 77 patients in the safety extension, 24 were randomized to placebo gel during the double-blind, placebo-controlled 12-week study. In the combined double-blind, placebo-controlled study and the open-label safety extension, a total of 441 patients were exposed to at least one dose of GELNIQUE 3%. 364 patients received at least 12 weeks of GELNIQUE 3% treatment and 66 patients received an additional 24 weeks of GELNIQUE 3% treatment during the open-label safety extension. The study population primarily consisted of women (87%) of Caucasian descent (87%) with an average age of 59 years who had <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> with urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>.</p>
<p>Table 1 lists adverse reactions (ARs), regardless of causality, that were reported in the randomized, double-blind, placebo-controlled 12-week study at an incidence greater than placebo and in greater than 3% of patients treated with GELNIQUE 3%.</p>
<p>Overall, 672 ARs were experienced by 51.9% of patients. Majority of the ARs were mild to moderate in intensity. The AR most commonly reported was <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> which was experienced by a greater proportion of patients in the oxybutynin group than the placebo group (26 patients [12.1%] in the oxybutynin 84 mg group, 10 patients [5.0%] in the placebo group). Application site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> was the next most commonly reported AR (8 patients [3.7%] in the oxybutynin 84 mg group and 2 patients [1.0%] in the placebo group). Other commonly reported ARs experienced by more patients in the oxybutynin groups compared with placebo were <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">application site rash</span> (7 patients [3.3%] in the oxybutynin 84 mg group and 1 patient [0.5%] in the placebo group); application site <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (6 patients [2.8%] in the oxybutynin 84 mg group and 1 patient [0.5%] in the placebo group).  The overall rate of application site adverse reactions of any kind was 14.2% in patients receiving GELNIQUE 3% as compared to 3.7% in patients receiving placebo.  Other cholinergic AEs &lt; 2% in occurrence include <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p>There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> during the study. There were no clinically meaningful changes in vital signs, laboratory values, or ECG examinations over the course of the study.</p>
<table>
<caption><span>Table 1: Commonly Reported Adverse Reactions that were reported in greater than 3% of patients treated with GELNIQUE 3% and at an incidence greater than placebo. </span></caption>
<col width="281">
<col width="104">
<col width="80">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> <span class="Bold">Treatment Group</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule">Preferred Term<span class="Sup">* </span>  </td>
<td class="Lrule Rrule Toprule" align="center"> <span class="Bold">Oxybutynin</span><span class="Bold"><br>84 mg/day</span><span class="Bold"><br>(N = 214)</span>
</td>
<td class="Lrule Rrule Toprule" align="center"> <span class="Bold">Placebo</span><span class="Bold"><br>(N = 202)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="bottom"></td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">n (%)</td>
<td class="Lrule Rrule Toprule" align="center" valign="bottom">n (%)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">     <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Lrule Rrule Toprule" align="center"> 26 (12.1)</td>
<td class="Lrule Rrule Toprule" align="center"> 10 (5.0)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">     Application site erythema                </td>
<td class="Lrule Rrule Toprule" align="center"> 8 (3.7)</td>
<td class="Lrule Rrule Toprule" align="center"> 2 (1.0)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule">     <span class="product-label-link" type="condition" conceptid="4319313" conceptname="Application site rash">Application site rash</span></td>
<td class="Lrule Rrule Toprule" align="center"> 7 (3.3)</td>
<td class="Lrule Rrule Toprule" align="center"> 1 (0.5)</td>
</tr>
</tbody>
</table>
<p><span class="Sup">* </span> Each patient is counted only once within each treatment, body system and preferred term. All percentages are based on number of patients in the ITT population within each treatment group as denominator.<br><br></p>
<p>During the 24-week open-label safety extension, the most commonly reported ARs were <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> reported in 4 patients each (5.2%), followed by <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and application site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (both occurred in 3 patients [3.9%]). One patient prematurely discontinued due to the application site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (both considered to be of mild severity). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.</span><span class="Bold">2</span><span class="Bold"> </span><span class="Bold">Po</span><span class="Bold">s</span><span class="Bold">t</span><span class="Bold">m</span><span class="Bold">a</span><span class="Bold">r</span><span class="Bold">k</span><span class="Bold">e</span><span class="Bold">t</span><span class="Bold">ing</span><span class="Bold"> </span><span class="Bold">E</span><span class="Bold">x</span><span class="Bold">perie</span><span class="Bold">n</span><span class="Bold">ce</span>
</h2>
<p class="First">The following adverse reactions have been identified during post approval use of GELNIQUE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Nervous System Disorders: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span><br>Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1><span class="Bold">7 DRUG INTERACTIONS</span></h1>
<p class="First">No specific drug-drug interaction studies have been performed with GELNIQUE 3%.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_7_1_Other_Anticholinergics"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 Other Anticholinergics</span></h2>
<p class="First">The concomitant use of GELNIQUE 3% with other anticholinergic (antimuscarinic) agents may increase the frequency and/or severity of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and other anticholinergic pharmacological effects. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1 Pregnancy</span></h2>
<p class="First">Pregnancy Category B.</p>
<p>There are no adequate and well-controlled studies of topical or oral oxybutynin use in pregnant women. Reproduction studies using oxybutynin chloride in the hamster, rabbit, rat, and mouse have shown no evidence of impaired fertility or harm to the fetus. The safety of GELNIQUE 3% administration to women who are or who may become pregnant has not been established. Therefore, GELNIQUE 3% should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.2 Labor and Delivery</span></h2>
<p class="First">GELNIQUE 3% has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.3 Nursing Mothers</span></h2>
<p class="First">It is not known whether oxybutynin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GELNIQUE 3% is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="_8_4_Pediatric_Use"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.4 Pediatric Use</span></h2>
<p class="First">The safety and effectiveness of GELNIQUE 3% have not been established in pediatric patients. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="_8_5_Geriatric_Use"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.5 Geriatric Use</span></h2>
<p class="First">Of the 424 patients exposed to GELNIQUE 3% in the randomized, double-blind, placebo-controlled 12-week study, 182 patients (34%) were 65 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_6_Renal_Impairment"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> received GELNIQUE 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_7_Hepatic_Impairment"></a><a name="section-8.7"></a><p></p>
<h2><span class="Bold">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> received GELNIQUE 3% during clinical trials. These trials were not designed to determine whether there were differences in safety or effectiveness in patients with or without impaired hepatic function. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">10 OVERDOSAGE</span></h1>
<p class="First">Overdosage with oxybutynin has been associated with anticholinergic effects including central nervous system excitation, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, exhaustion, heat sensitivity, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Oral ingestion of 100 mg oxybutynin chloride in association with alcohol has been reported in a 13-year-old who experienced <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, and in a 34-year-old who developed <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, followed by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> on awakening, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">retention of urine</span>. Both patients recovered fully with symptomatic treatment. If overexposure occurs, monitor patients until symptoms resolve.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1><span class="Bold">11 DESCRIPTION</span></h1>
<p class="First">Oxybutynin is an antispasmodic, antimuscarinic agent. GELNIQUE 3% is a topical, homogeneous, very lightly to moderately opalescent, translucent colorless to slightly colored gel, without particles. The product is a hydroalcoholic gel containing 30 mg oxybutynin per gram of gel. GELNIQUE 3% is available in a 0.92 gram (1 mL) unit dose that contains 28 mg oxybutynin. Oxybutynin is delivered as a racemate of R- and S-isomers. Chemically, oxybutynin base is d, l (racemic) 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate.</p>
<p>The empirical formula of oxybutynin base is C<span class="Sub">22</span>H<span class="Sub">31</span>NO<span class="Sub">3</span>. Its structural formula is:</p>
<p><img alt="Structural formula for Gelnique 3%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6754623-b14c-4fc3-8719-48eee3119156&amp;name=gelnique-3-percent-01.jpg">                           </p>
<p>Oxybutynin is a white powder with a molecular weight of 357.</p>
<p>Inactive ingredients in GELNIQUE 3% are diethylene glycol monoethyl ether, NF; alcohol, USP; hydroxypropyl cellulose, NF; propylene glycol, NF; butylated hydroxytoluene, NF; HCl 0.1 M, NF; and purified water, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1><span class="Bold">12 CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action</span></h2>
<p class="First">Oxybutynin is a racemic (50:50) mixture of R- and S- isomers. Antimuscarinic activity resides predominantly with the R-isomer. </p>
<p>Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle. The active metabolite, N-desethyloxybutynin, has pharmacological activity on the human detrusor muscle that is similar to that of oxybutynin in <span class="Italics">in vitro</span> studies.  In patients with conditions characterized by involuntary detrusor contractions, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="_12_3_Pharmacokinetics"></a><a name="section-11.2"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics</span></h2>
<p class="First">Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum. Steady-state concentrations are achieved within 3 days of continuous dosing. </p>
<p><span class="Italics">Absorption</span></p>
<p>Absorption of oxybutynin is similar when GELNIQUE 3% is applied to the abdomen, upper arm/shoulders or thighs. The pharmacokinetic parameters and mean plasma concentrations during a randomized, crossover study of the three recommended application sites in 25 healthy men and women are shown in Table 2 and Figure 1, respectively.</p>
<table>
<caption><span>Table 2: Pharmacokinetic Parameters (mean values) for Oxybutynin (84 mg/day) 3% gel.</span></caption>
<col width="152">
<col width="86">
<col width="105">
<col width="71">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"><span class="Bold"> Application Site</span></td>
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold"> </span><span class="Bold">AUC</span><span class="Bold"><span class="Sub">0-t</span></span><span class="Bold"> </span><br><span class="Bold"> </span><span class="Bold">(ng·h/mL) </span>
</td>
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold"> C</span><span class="Bold"><span class="Sub">max </span></span><span class="Bold">(ng/mL)</span>
</td>
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold"> T </span><span class="Bold"><span class="Sub">max </span></span><span class="Bold">(h)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Abdomen</td>
<td class="Lrule Rrule Toprule" align="center"> 284.1</td>
<td class="Lrule Rrule Toprule" align="center"> 6.3</td>
<td class="Lrule Rrule Toprule" align="center"> 24</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Thigh</td>
<td class="Lrule Rrule Toprule" align="center"> 286.9</td>
<td class="Lrule Rrule Toprule" align="center"> 5.8</td>
<td class="Lrule Rrule Toprule" align="center"> 36</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule"> Upper Arm/Shoulder</td>
<td class="Lrule Rrule Toprule" align="center"> 329.1</td>
<td class="Lrule Rrule Toprule" align="center"> 8.8</td>
<td class="Lrule Rrule Toprule" align="center"> 24</td>
</tr>
</tbody>
</table>
<div class="Figure">
<img alt="Figure 1: Mean (including SD) plasma oxybutynin concentrations versus time after application of GELNIQUE 3% to the abdomen (Site A), thigh (Site B), and upper arm/shoulder (Site C) (N = 25)." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6754623-b14c-4fc3-8719-48eee3119156&amp;name=gelnique-3-percent-02.jpg"><p class="MultiMediaCaption">Figure 1: Mean (including SD) plasma oxybutynin concentrations versus time after application of GELNIQUE 3% to the abdomen (Site A), thigh (Site B), and upper arm/shoulder (Site C) (N = 25).</p>
</div>
<p><span class="Italics">Distribution</span></p>
<p>Oxybutynin is widely distributed in body tissues following systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg oxybutynin chloride.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include N-desethyloxybutynin (DEO), which is pharmacologically active and phenylcyclohexylglycolic acid, which is pharmacologically inactive.</p>
<p>Transdermal administration of oxybutynin bypasses the first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyloxybutynin metabolite. Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transdermal absorption. The AUC ratio of N-desethyloxybutynin metabolite to parent compound following multiple transdermal applications is approximately 1:1 for GELNIQUE 3%. The apparent half-life was approximately 30 hours.</p>
<p><span class="Italics">Excretion</span></p>
<p>Oxybutynin undergoes extensive hepatic metabolism, with less than 0.1% of the administered dose excreted unchanged in the urine. Less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.</p>
<p><span class="Italics">Person-to-Person Transference</span></p>
<p>The potential for dermal transfer of oxybutynin from a treated person to an untreated person was evaluated in a single-dose study where subjects dosed with GELNIQUE 3% engaged in vigorous contact with an untreated partner for 15 minutes, either with (N = 14 couples) or without (N = 14 couples) clothing covering the application area. The untreated partners not protected by clothing demonstrated low detectable plasma concentrations of oxybutynin (mean C<span class="Sub">max</span> = 0.65 ng/mL). Only one of the 14 untreated subjects participating in the clothing-to-skin contact regimen had very low measurable oxybutynin plasma concentrations (C<span class="Sub">max</span> = 0.06 ng/mL) during the 24 hours following contact with treated subjects; oxybutynin was not detectable with the remaining 13 untreated subjects. Regardless of the low exposure observed in this study, patients should avoid skin-to-skin contact with partners after applying the gel.</p>
<p><span class="Italics">Use of Sunscreen</span></p>
<p>The effect of sunscreen on the absorption of oxybutynin when applied 30 minutes before or 30 minutes after GELNIQUE 3% application was evaluated in a single-dose randomized crossover study (N = 20). Concomitant application of sunscreen, either before or after GELNIQUE 3% application, had no effect on the systemic exposure of oxybutynin.</p>
<p><span class="Italics">Showering</span></p>
<p>The effect of showering on the absorption of oxybutynin was evaluated in a randomized, steady-state crossover study under conditions of no shower, or showering 1, 2 or 6 hours after GELNIQUE 3% application (N = 22). The results of the study indicate that showering one hour after administration does not affect the overall systemic exposure to oxybutynin.</p>
<p><span class="Italics">Race</span></p>
<p>The effect of race on the pharmacokinetics of GELNIQUE 3% has not been studied.</p>
<p><span class="Italics">Geriatric Patients</span></p>
<p>Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on geriatric status in patients following administration of GELNIQUE 3% <span class="Italics">[see </span><span class="Italics"><a href="#_8_5_Geriatric_Use">Use in Specific Populations (8.5)</a></span>].</p>
<p><span class="Italics">Pediatric Patients</span></p>
<p>The pharmacokinetics of oxybutynin and N-desethyloxybutynin following application of GELNIQUE 3% has not been evaluated in individuals younger than 18 years of age <span class="Italics">[see </span><span class="Italics"><a href="#_8_4_Pediatric_Use">Use in Specific Populations (8.4)</a></span>].</p>
<p><span class="Italics">Gender</span></p>
<p>Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on gender in healthy volunteers following administration of GELNIQUE 3%.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>There is limited experience with the use of GELNIQUE 3% in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> <span class="Italics">[see </span><span class="Italics"><a href="#_8_6_Renal_Impairment">Use in Specific Populations (8.6)</a></span>].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>There is limited experience with the use of GELNIQUE 3% in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics">[see </span><span class="Italics"><a href="#_8_7_Hepatic_Impairment">Use in Specific Populations (8.7)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">A 24-month study in rats at dosages of oxybutynin chloride of 20, 80, and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25, and 50 times the maximum exposure in humans taking an oral dose, based on body surface area. Oxybutynin chloride showed no increase of mutagenic activity when tested in <span class="Italics">Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae,</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> test systems. Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no evidence of impaired fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="_14_CLINICAL_STUDIES"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14 CLINICAL STUDIES</span></h1>
<p class="First">The efficacy and safety of GELNIQUE 3% were evaluated in a single randomized, double-blind, placebo-controlled, multicenter 12-week study in patients with <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and urge and mixed <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> with a predominance of <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span> episodes.  This was followed by an open-label safety extension. Key entry criteria included adults with <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> (OAB) symptoms for at least 3 months who were either treatment-naïve or had demonstrated a beneficial response to anticholinergic treatment for OAB. Subjects were randomly assigned to receive 84 mg/day oxybutynin, 56 mg/day oxybutynin, or placebo. A total of 214 patients received 84 mg/day oxybutynin, 210 patients received 56 mg/day oxybutynin, and 202 patients received placebo gel. The majority of patients were Caucasian (87%) and female (87%), with a mean age of 59 years (range: 19 to 89 years). The primary efficacy endpoint was the change from baseline to week 12 in the number of <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> episodes (UIE) per week, as determined from a 3‑day patient daily diary.</p>
<p>Patients treated with GELNIQUE 3% (84 mg) experienced a statistically significant decrease in the number of <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> episodes per week from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p = 0.0445) and patients treated with the 56 mg dose did not show statistically significant efficacy.  Statistically significant improvements in daily <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> (p = 0.0010) and urinary void volume (p &lt; 0.0001) were also seen with GELNIQUE 3% (84 mg) relative to placebo.  The mean difference from placebo for GELNIQUE 3% (84 mg) was -2.3 for <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> episodes per week in a group of patients with a mean of greater than 40 <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> episodes per week at baseline.  Mean and median change from baseline in weekly <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> episodes (primary endpoint), daily <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, and urinary void volume (secondary endpoints) between placebo and GELNIQUE 3% are summarized in Table 3.</p>
<table>
<caption><span>Table 3: Mean (SD) and median change from baseline to Week 12 in <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> episodes, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, and urinary void volume: Intent-To-Treat population (LOCF<span class="Sup">¶ </span>).</span></caption>
<col width="157">
<col width="156">
<col width="135">
<col width="107">
<col width="85">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"> <br><span class="Bold">Parameter</span> </td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold">Placebo</span><span class="Bold"><br>(N = 202) </span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold"> GELNIQUE 3% (84 mg/day)</span><span class="Bold"><br>(N = 214)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule Toprule" align="center"> Mean (SD)</td>
<td class="Lrule Rrule Toprule" align="center"> Median</td>
<td class="Lrule Rrule Toprule" align="center"> Mean (SD)</td>
<td class="Lrule Rrule Toprule" align="center"> Median</td>
</tr>
<tr><td class="Lrule Rrule Toprule" colspan="5"><span class="Bold">     Weekly <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary Incontinence</span> Episodes</span></td></tr>
<tr>
<td class="Lrule Rrule Toprule"> Baseline</td>
<td class="Lrule Rrule Toprule" align="center"> 45.8 (31.87)</td>
<td class="Lrule Rrule Toprule" align="center"> 40.9</td>
<td class="Lrule Rrule Toprule" align="center"> 43.6 (27.90)</td>
<td class="Lrule Rrule Toprule" align="center"> 37.3</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Reduction</td>
<td class="Lrule Rrule Toprule" align="center"> -18.1 (28.81)</td>
<td class="Lrule Rrule Toprule" align="center"> -14.0</td>
<td class="Lrule Rrule Toprule" align="center"> -20.4 (24.39)</td>
<td class="Lrule Rrule Toprule" align="center"> -16.4</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" colspan="3"> Mean difference [GELNIQUE 3% – placebo] (SE)</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> -2.3 (2.65)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" colspan="3"> P-value<span class="Sup">† </span>vs. placebo</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 0.0445<span class="Sup">‡ </span> </td>
</tr>
<tr><td class="Lrule Rrule Toprule" colspan="5">     <span class="Bold">Daily <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span></span>
</td></tr>
<tr>
<td class="Lrule Rrule Toprule"> Baseline</td>
<td class="Lrule Rrule Toprule" align="center"> 11.5 (3.34)</td>
<td class="Lrule Rrule Toprule" align="center"> 11.0</td>
<td class="Lrule Rrule Toprule" align="center"> 11.3 (2.87)</td>
<td class="Lrule Rrule Toprule" align="center"> 10.7</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Reduction</td>
<td class="Lrule Rrule Toprule" align="center"> -1.9 (3.34)</td>
<td class="Lrule Rrule Toprule" align="center"> - 1.7</td>
<td class="Lrule Rrule Toprule" align="center"> - 2.6 (2.66)</td>
<td class="Lrule Rrule Toprule" align="center"> - 2.3</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" colspan="3">Mean difference [GELNIQUE 3% - placebo] (SE)</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> - 0.7 (0.30)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" colspan="3"> P-value<span class="Sup">† </span>vs. placebo</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 0.0010<span class="Sup">§ </span> </td>
</tr>
<tr><td class="Lrule Rrule Toprule" colspan="5"><span class="Bold">     Urinary Void Volume (mL)</span></td></tr>
<tr>
<td class="Lrule Rrule Toprule"> Baseline</td>
<td class="Lrule Rrule Toprule" align="center"> 184.5 (85.71)</td>
<td class="Lrule Rrule Toprule" align="center"> 173.4</td>
<td class="Lrule Rrule Toprule" align="center"> 196.9 (88.11)</td>
<td class="Lrule Rrule Toprule" align="center"> 189.2</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"> Increase</td>
<td class="Lrule Rrule Toprule" align="center"> 9.8 (64.98)</td>
<td class="Lrule Rrule Toprule" align="center"> 5.7</td>
<td class="Lrule Rrule Toprule" align="center"> 32.7 (77.25)</td>
<td class="Lrule Rrule Toprule" align="center"> 26.6</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" colspan="3"> Mean difference [GELNIQUE 3% – placebo] (SE)</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> 23.0  (7.24)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" colspan="3"> P-value<span class="Sup">† </span>vs. placebo</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2"> &lt; 0.0001<span class="Sup">§ </span> </td>
</tr>
</tbody>
</table>
<p><span class="Sup">¶ </span> Last-Observation-Carried-Forward imputation for missing data<br><span class="Sup">† </span> P-value is based on ANCOVA analysis on rank-transformed data<br><span class="Sup">‡ </span> Comparison is significant if p ≤ 0.05<br><span class="Sup">§ </span> Comparison is significant if p ≤ 0.0125, adjusting for multiplicity<br><br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<p class="First">GELNIQUE 3% (oxybutynin) gel 3% is supplied in a metered-dose pump dispenser composed of an inner aluminum laminated foil liner encased in a rigid plastic bottle with a plastic cap. The nozzle of the pump dispenser is sealed by a removable cap attached to the actuator by a plastic string.</p>
<p><span class="Underline">How Supplied</span></p>
<p>NDC 52544-041-54   100 mL (92 g) metered pump dispenser containing 90 metered 0.92 g (1 mL) pumps delivering 28 mg oxybutynin per pump actuation.</p>
<p><span class="Underline">Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). See USP controlled room temperature. Protect from moisture and humidity. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></h1>
<p class="First">See FDA-approved patient labeling (Patient Information)</p>
<p><span class="Bold">Instructions for Use</span></p>
<p>Inform patients of the following:</p>
<ul class="Disc">
<li>GELNIQUE 3% is for topical application only and should not be ingested.  Keep out of reach of children.<br>
</li>
<li>GELNIQUE 3% should be applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs.<br>
</li>
<li>Do not use any GELNIQUE 3% that came out while priming.<br>
</li>
<li>Apply immediately after actuating the dose.  <br>
</li>
<li>Application sites may be rotated to reduce the potential for local site reactions.<br>
</li>
<li>GELNIQUE 3% should not be applied to recently shaved skin surfaces. Avoid skin with open sores, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, irritation, <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, and tattoos.<br>
</li>
<li>Do not apply the gel to the breasts or genital area.<br>
</li>
<li>Discard used pump dispensers in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.<br>
</li>
<li>Wash hands immediately after product application.<br>
</li>
<li>Do not shower or immerse the application site in water for 1 hour after product application.<br>
</li>
<li>Cover the application sites with clothing if skin-to-skin contact at the application site is anticipated.<br>
</li>
<li>Alcohol based gels are flammable. Avoid open fire or smoking until the gel has dried.<br>
</li>
<li>If you get the gel in your eyes, thoroughly rinse your eyes right away with warm, clean water to flush out any gel. Seek medical attention if needed.</li>
</ul>
<p><span class="Bold">Important Anticholinergic Adverse Reactions</span></p>
<p>Patients should be informed that anticholinergic (antimuscarinic) agents, such as GELNIQUE 3%, may produce clinically significant adverse reactions related to anticholinergic pharmacological activity. <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">Heat prostration</span> (due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>) can occur when anticholinergics such as GELNIQUE 3% are used in a hot environment. Because anticholinergic (antimuscarinic) agents, such as GELNIQUE 3%, may produce <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until this product's effects have been determined. Patients should be informed that alcohol may enhance the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> caused by anticholinergic (antimuscarinic) agents such as GELNIQUE 3%. </p>
<p>For all medical inquiries contact:<br>ACTAVIS<br>Medical Communications<br>Parsippany, NJ 07054<br>1-800-272-5525</p>
<p>Distributed By:<br>Actavis Pharma, Inc.<br>Parsippany, NJ 07054 USA</p>
<p>Content Updated: July 2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-approved patient labeling</span></p>
<p><span class="Bold">Patient Information</span><span class="Bold"><br>GELNIQUE [Gel-nēk] 3%</span><br>(oxybutynin) gel 3%<br>Topical</p>
<p><span class="Bold">Important: For use on the skin only (topical). Do not get GELNIQUE 3% in or near your eyes, nose, or mouth.</span><br><br>Read this Patient Information carefully before you use GELNIQUE 3% and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. </p>
<p><span class="Bold">What is GELNIQUE 3%?</span></p>
<p>GELNIQUE 3% is a prescription medicine used to treat the symptoms of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> including:</p>
<ul class="Disc">
<li>a strong need to urinate with leaking or wetting <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span> (urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>)<br>
</li>
<li>a strong need to urinate right away (urgency)<br>
</li>
<li>urinating often (frequency) </li>
</ul>
<p>It is not known if GELNIQUE 3% is safe or effective in children.</p>
<p><span class="Bold">Who should not use GELNIQUE 3%?</span><span class="Bold"><br>Do not use GELNIQUE 3% if:</span></p>
<ul class="Disc">
<li>Your bladder does not empty or does not empty completely when you urinate (<span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>).<br>
</li>
<li>Your stomach empties slowly or incompletely after a meal (gastric retention).<br>
</li>
<li>You have high pressure in your eye (uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>).<br>
</li>
<li>You have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to oxybutynin or any of the ingredients in GELNIQUE 3%.  See the end of this leaflet for a complete list of ingredients in GELNIQUE 3%.</li>
</ul>
<p>Talk to your healthcare provider before taking this medicine if you have any of these conditions.</p>
<p><span class="Bold">What should I tell my doctor before using GELNIQUE 3%?</span><span class="Bold"><br>Before you use GELNIQUE 3%, tell your doctor if you:</span></p>
<ul class="Disc">
<li>have problems emptying your bladder completely<br>
</li>
<li>have stomach problems including:<br>•  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or difficulty in emptying your bowels<br>•  inflamed bowels (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>)<br>•  <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the tube between your mouth and stomach (gastric reflux disease or <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>)<br>
</li>
<li>have <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">generalized muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>)<br>
</li>
<li>are pregnant or are planning to become pregnant. It is not known if GELNIQUE 3% will harm your unborn baby.<br>
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if GELNIQUE 3% passes into your breast milk. Talk to your doctor about the best way to feed your baby if you use GELNIQUE 3%.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<p>GELNIQUE 3% may affect the way other medicines work, and other medicines may affect how GELNIQUE 3% works.<br><br>Especially tell your doctor if you take:</p>
<ul class="Disc">
<li>medicines used to treat <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (Bisphosphonates)<br>
</li>
<li>other medicines used to treat <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> (Anticholinergic)</li>
</ul>
<p>Ask your doctor if you are not sure if your medicine is one listed above.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use GELNIQUE 3%? </span><span class="Bold"><br>GELNIQUE 3% is for skin use only.</span></p>
<ul class="Disc">
<li>Use GELNIQUE 3% exactly as your doctor tells you to use it.<br>
</li>
<li>GELNIQUE 3% should only be applied to dry intact skin on your stomach (abdomen), upper arms, or thighs.<br>
</li>
<li>Do not put GELNIQUE 3% on recently shaved skin, open sores, <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, tattoos, or skin with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>.<br>
</li>
<li>Do not put GELNIQUE 3% on your breasts or genital area.<br>
</li>
<li>
<span class="Bold">GELNIQUE 3% contains alcohol and is flammable. Avoid fire, flames, or smoking until the product has dried.</span><br>
</li>
<li>Cover the application site with clothing after the gel has dried, if skin-to-skin contact between another person and the application site is expected.<br>
</li>
<li>After applying GELNIQUE 3%, wash your hands with soap and water right away.<br>
</li>
<li>GELNIQUE 3% may be used with sunscreen.<br>
</li>
<li>
<span class="Bold">If you get GELNIQUE 3% in your eyes: </span>Rinse your eyes well right away with clean and warm water. Seek medical attention if needed.</li>
</ul>
<p><span class="Bold">How to use the GELNIQUE 3% pump:</span></p>
<p><img alt="How to use the GELNIQUE 3% pump" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6754623-b14c-4fc3-8719-48eee3119156&amp;name=gelnique-3-percent-03.jpg"></p>
<p><span class="Bold">You must prime the pump before you use it for the first time.</span><span class="Bold"><br>To prime the pump:</span></p>
<ul class="Disc">
<li>To prime the GELNIQUE 3% pump, hold the pump upright and fully press down (depress) the pump 4 times. Now GELNIQUE 3% is ready to use.<br>
</li>
<li>Do not use any product that came out while priming.</li>
</ul>
<p><span class="Bold">Applying GELNIQUE 3%:</span><span class="Bold"><br>1. Selecting your application site:</span></p>
<p><span class="Bold">Apply GELNIQUE 3% only to 1 of the shaded areas shown in the figure below: (See Figure A).</span></p>
<ul class="Disc">
<li>stomach area (abdomen)<br>
</li>
<li>upper arms<br>
</li>
<li>shoulders<br>
</li>
<li>thighs</li>
</ul>
<p><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6754623-b14c-4fc3-8719-48eee3119156&amp;name=gelnique-3-percent-04.jpg"></p>
<ul class="Disc">
<li>Wash the area where GELNIQUE 3% will be applied with mild soap and water. Allow the area to dry completely.<br>
</li>
<li>Wash your hands with soap and water.<br>
</li>
<li>Application sites may be rotated to reduce the potential for local site reactions.</li>
</ul>
<p><span class="Bold">2. Dispensing your dose of GELNIQUE 3%:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Place your hand under the pump.</span>  Press the pump all the way down 3 times <span class="Bold">(See Figure B). </span>You can also place the pump right over the application site then press the pump all the way down 3 times to dispense your dose <span class="Bold">(See Figure C).</span><br>
</li>
<li>You should apply GELNIQUE 3% right after you dispense your dose.<br>
</li>
<li>Wash your hands with soap and water right away.</li>
</ul>
<p><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6754623-b14c-4fc3-8719-48eee3119156&amp;name=gelnique-3-percent-05.jpg"></p>
<p><span class="Bold">What should I avoid while using GELNIQUE 3%?</span></p>
<ul class="Disc">
<li>Do not take a bath, swim, shower, exercise, or get the application site wet for 1 hour after you apply your dose.<br>
</li>
<li>GELNIQUE 3% can cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Do not drive, operate heavy machinery, or do other dangerous activities until you know how GELNIQUE 3% affects you.<br>
</li>
<li>You should not drink alcohol while using GELNIQUE 3%. It can increase your chances of getting serious side effects.</li>
</ul>
<p><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6754623-b14c-4fc3-8719-48eee3119156&amp;name=gelnique-3-percent-06.jpg"></p>
<p><span class="Bold">What are the possible side effects of GELNIQUE 3%?</span><span class="Bold"><br>The most common side effects of GELNIQUE 3% include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurry vision</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the application site</li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of GELNIQUE 3%. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store GELNIQUE 3%?</span></p>
<ul class="Disc"><li>Store GELNIQUE 3% at room temperature between 68ºF to 77ºF (20ºC to 25ºC).</li></ul>
<p><span class="Bold">Keep GELNIQUE 3% and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of GELNIQUE 3%.</span><br>Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Do not use GELNIQUE 3% for a condition for which it was not prescribed. Do not give GELNIQUE 3% to other people, even if they have the same symptoms you have. It may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about GELNIQUE 3%. If you would like more information about GELNIQUE 3%, talk with your doctor. You can ask your pharmacist or doctor for information about GELNIQUE 3% that is written for health professionals. </p>
<p>For more information go to <span class="Underline">www.gelnique.com</span> or call 1-800-272-5525.</p>
<p><span class="Bold">What are the ingredients in GELNIQUE 3%?</span><span class="Bold"><br>Active ingredient: </span>oxybutynin<br><span class="Bold">Inactive ingredients: </span>diethylene glycol monoethyl ether, NF; alcohol, USP; hydroxypropyl cellulose, NF; propylene glycol, NF; butylated hydroxytoluene, NF; HCl 0.1 M, NF; and purified water, USP.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>For all medical inquiries contact:<br>ACTAVIS<br>Medical Communications<br>Parsippany, NJ 07054<br>1-800-272-5525</p>
<p>Distributed By:<br>Actavis Pharma, Inc.<br>Parsippany, NJ 07054 USA</p>
<p>Content Updated: January 2013</p>
<p>219404-01</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First"><span class="Bold">NDC 52544-041-54</span><span class="Bold"><br>Rx Only</span><span class="Bold"><br>Gelnique 3%</span><span class="Bold"><br>(oxybutynin) gel 3%</span><br><span class="Bold">92 g </span><span class="Bold">providing</span><span class="Bold"><br>30 metered doses</span><span class="Bold"><br>(3 pumps per dose)</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL
NDC 52544-041-54
Rx Only
Gelnique 3%
(oxybutynin) gel 3%
92 g providing
30 metered doses
(3 pumps per dose)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c6754623-b14c-4fc3-8719-48eee3119156&amp;name=gelnique-3-percent-07.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GELNIQUE 		
					</strong><br><span class="contentTableReg">oxybutynin gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52544-041</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TRANSDERMAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYBUTYNIN</strong> (OXYBUTYNIN) </td>
<td class="formItem">OXYBUTYNIN</td>
<td class="formItem">28 mg  in .92 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIETHYLENE GLYCOL MONOETHYL ETHER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52544-041-54</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">92 g in 1 BOTTLE, PUMP; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202513</td>
<td class="formItem">04/02/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Pharma, Inc.
							(119723554)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>eab01b57-bd14-4f36-9a81-f63d250fd132</div>
<div>Set id: c6754623-b14c-4fc3-8719-48eee3119156</div>
<div>Version: 6</div>
<div>Effective Time: 20150720</div>
</div>
</div> <div class="DistributorName">Actavis Pharma, Inc.</div></p>
</body></html>
